Quick Answer
Estrella Immunopharma, Inc. reported Net Income Loss of -$13.06 million for the year ending 2025.
- Estrella Immunopharma, Inc. showed a decrease of -78.7% in Net Income Loss from 2024 to 2025.
- This data is from Estrella Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$819.00 | Q2 2021: -$3.6 thousand | Q3 2021: -$107.5 thousand | Q1 2022: -$141.3 thousand | Q2 2022: -$359.6 thousand | Q3 2022: -$2.89 million | Q4 2022: -$2.76 million | Q1 2023: -$2.74 million | Q2 2023: -$76.0 thousand | Q3 2023: -$1.87 million | Q4 2023: -$1.02 million | Q1 2024: -$469.5 thousand | Q2 2024: -$3.95 million | Q3 2024: -$3.38 million | Q1 2025: -$2.10 million | Q2 2025: -$5.54 million | Q3 2025: -$4.80 million.
- Over the full 5 years of available data (2021 to 2025), Estrella Immunopharma, Inc.'s Net Income Loss has declined by 5,173.5%.
- Historical annual values: Fiscal year 2025: -$13.06 million | Fiscal year 2024: -$7.31 million | Fiscal year 2023: -$11.11 million | Fiscal year 2022: -$996.1 thousand | Fiscal year 2021: -$247.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: